DolCas Biotech Receives FDA “No Objection” Letter following GRAS Review for BCM-95 Curcumin Ingredient
The company also secured self-affirmed GRAS status for its ingredient back in 2016.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Jennifer Prince Tags: Herbs & Botanicals Regulatory Source Type: news